Macrogenics (MGNX) Operating Leases (2012 - 2026)
Macrogenics (MGNX) posted quarterly Operating Leases of $31.3 million for Q1 2026, down 2.5% year-over-year from $32.1 million in Q1 2025, and down 0.92% quarter-over-quarter from $31.6 million in Q4 2025.
Macrogenics (MGNX) Operating Leases (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Operating Leases for 13 consecutive years, with $31.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 2.5% year-over-year to $31.3 million; the TTM figure through Mar 2026 stood at $31.3 million (down 2.5% YoY), while the FY2025 annual figure was $31.6 million, down 3.1% from the prior year.
- Operating Leases eased to $31.3 million in Q1 2026 per MGNX's latest filing, from $31.6 million in the prior quarter.
- Across five years, Operating Leases topped out at $32.6 million in Q4 2024 and bottomed at $17.0 million in Q3 2022.
- Historically, Operating Leases has averaged $28.6 million across 5 years, with a median of $30.2 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases slipped 22.81% — and 2023, when it jumped 77.54%.
- Macrogenics' Operating Leases stood at $30.1 million in 2022, then rose by 0.3% to $30.2 million in 2023, then increased by 7.95% to $32.6 million in 2024, then decreased by 3.1% to $31.6 million in 2025, then dropped by 0.92% to $31.3 million in 2026.
- Business Quant data shows MGNX's Operating Leases at $31.3 million in Q1 2026, $31.6 million in Q4 2025, and $31.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.30 Mn |
| Dec 31, 2025 | 31.59 Mn |
| Sep 30, 2025 | 31.87 Mn |
| Jun 30, 2025 | 32.13 Mn |
| Mar 31, 2025 | 32.10 Mn |
| Dec 31, 2024 | 32.60 Mn |
| Sep 30, 2024 | 29.36 Mn |
| Jun 30, 2024 | 29.65 Mn |
| Mar 31, 2024 | 29.93 Mn |
| Dec 31, 2023 | 30.20 Mn |
| Sep 30, 2023 | 30.18 Mn |
| Jun 30, 2023 | 30.16 Mn |
| Mar 31, 2023 | 30.13 Mn |
| Dec 31, 2022 | 30.11 Mn |
| Sep 30, 2022 | 17.00 Mn |
| Jun 30, 2022 | 18.26 Mn |
| Mar 31, 2022 | 19.51 Mn |
| Dec 31, 2021 | 20.79 Mn |
| Sep 30, 2021 | 22.03 Mn |
| Jun 30, 2021 | 23.21 Mn |